TY - JOUR
T1 - Patient-Reported Outcomes of Oligometastatic Patients After Conventional or Stereotactic Radiation Therapy to Bone Metastases
T2 - An Analysis of the PRESENT Cohort
AU - van de Ven, Saskia
AU - van den Bongard, Desiree
AU - Pielkenrood, Bart
AU - Kasperts, Nicolien
AU - Eppinga, Wietse
AU - Peters, Max
AU - Verkooijen, Helena
AU - van der Velden, Joanne
N1 - Copyright © 2020 Elsevier Inc. All rights reserved.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - PURPOSE: Stereotactic body radiation therapy (SBRT) has become a widely adopted treatment for patients with oligometastatic disease, despite limited evidence of superiority. We compared pain response and quality of life (QoL) in patients with oligometastatic disease treated with conventionally fractionated 3-dimensional radiation therapy (3DCRT) or SBRT to bone metastases.METHODS AND MATERIALS: We included patients with oligometastatic disease (≤5 lesions within ≤3 organs) treated within the prospective PRESENT cohort. Main outcomes were pain response, clinical local control, and QoL 2, 4, and 8 weeks and 3, 6, and 12 months after treatment. Pain response was assessed only in patients who reported pain at baseline and was defined according to international consensus criteria.RESULTS: Of 131 patients with oligometastatic disease, 66 patients were treated with 3DCRT and 65 patients with SBRT. A pain response was achieved in 81% (3DCRT) versus 84% (SBRT) with a median duration of 23 weeks (range, 1-58) and 24 weeks (range, 0-50), respectively. Reirradiation was needed in 33% versus 5% of the patients, respectively. None of the QoL subscales were significantly different between both groups.CONCLUSIONS: In patients with oligometastatic disease, SBRT to bone metastases did not improve pain response or QoL compared with 3DCRT. Reirradiation was less often needed in the SBRT group.
AB - PURPOSE: Stereotactic body radiation therapy (SBRT) has become a widely adopted treatment for patients with oligometastatic disease, despite limited evidence of superiority. We compared pain response and quality of life (QoL) in patients with oligometastatic disease treated with conventionally fractionated 3-dimensional radiation therapy (3DCRT) or SBRT to bone metastases.METHODS AND MATERIALS: We included patients with oligometastatic disease (≤5 lesions within ≤3 organs) treated within the prospective PRESENT cohort. Main outcomes were pain response, clinical local control, and QoL 2, 4, and 8 weeks and 3, 6, and 12 months after treatment. Pain response was assessed only in patients who reported pain at baseline and was defined according to international consensus criteria.RESULTS: Of 131 patients with oligometastatic disease, 66 patients were treated with 3DCRT and 65 patients with SBRT. A pain response was achieved in 81% (3DCRT) versus 84% (SBRT) with a median duration of 23 weeks (range, 1-58) and 24 weeks (range, 0-50), respectively. Reirradiation was needed in 33% versus 5% of the patients, respectively. None of the QoL subscales were significantly different between both groups.CONCLUSIONS: In patients with oligometastatic disease, SBRT to bone metastases did not improve pain response or QoL compared with 3DCRT. Reirradiation was less often needed in the SBRT group.
KW - Aged
KW - Bone Neoplasms/radiotherapy
KW - Cohort Studies
KW - Dose Fractionation, Radiation
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Neoplasm Metastasis
KW - Patient Reported Outcome Measures
KW - Radiosurgery
UR - http://www.scopus.com/inward/record.url?scp=85080095971&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2019.12.041
DO - 10.1016/j.ijrobp.2019.12.041
M3 - Article
C2 - 32007565
SN - 0360-3016
VL - 107
SP - 39
EP - 47
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 1
ER -